Repligen Exceeds Q4 & Full Year 2025 Revenue Guidance, Projects Strong 2026 Growth and Margin Expansion
Summary
Repligen reported Q4 and full year 2025 financial results that exceeded prior guidance and provided strong 2026 revenue and margin expansion guidance.
Key Events
-
Q4 2025 Revenue Beat
Reported fourth quarter revenue of $198 million, an 18% year-over-year increase, exceeding the high end of previous guidance.
-
Full Year 2025 Strong Performance
Achieved full year 2025 revenue of $738 million, up 16% year-over-year, with 16% organic non-COVID growth.
-
Positive 2026 Guidance
Forecasts full year 2026 revenue of $810 million to $840 million (10-14% growth) and 150 basis points of adjusted operating margin expansion.
-
Return to GAAP Profitability
GAAP net income turned positive for both Q4 ($13 million) and full year 2025 ($49 million), reversing losses from the prior year.
Analysis
Repligen Corporation reported robust financial results for the fourth quarter and full year 2025, surpassing the high end of its previous revenue and adjusted operating income guidance. This strong performance is expected to continue into 2026, with management forecasting 10-14% revenue growth and a significant 150 basis point expansion in adjusted operating margin. The positive outlook, driven by traction across its differentiated portfolio and strategic investments, suggests continued operational strength and improved profitability.
At the time of this filing, RGEN was trading at $137.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $102.97 to $175.77. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.